about
Regulation of Multi-drug Resistance in hepatocellular carcinoma cells is TRPC6/Calcium Dependent.NANOMEDICINE: will it offer possibilities to overcome multiple drug resistance in cancer?Controlled breast cancer microarrays for the deconvolution of cellular multilayering and density effects upon drug responsesCodelivery of chemotherapeutics via crosslinked multilamellar liposomal vesicles to overcome multidrug resistance in tumorMiniaturized pre-clinical cancer models as research and diagnostic tools.Thermal dose fractionation affects tumour physiological responseImpact of preoperative anemia on relapse and survival in breast cancer patients.Bioengineered human arginase I with enhanced activity and stability controls hepatocellular and pancreatic carcinoma xenografts.Preoperative anemia, blood transfusion, and neutrophil-to-lymphocyte ratio in patients with stage i non-small cell lung cancer.The use of nanoparticle-mediated targeted gene silencing and drug delivery to overcome tumor drug resistance.Hypoxia-driven immunosuppression: a new reason to use thermal therapy in the treatment of cancer?Human tumor xenografts and mouse models of human tumors: re-discovering the models.Histopathological determinants of tumor resistance: a special look to the immunohistochemical expression of carbonic anhydrase IX in human cancers.The use of porous scaffold as a tumor model.Targeted therapy and personalized medicine in hepatocellular carcinoma: drug resistance, mechanisms, and treatment strategies.Targeting acute hypoxic cancer cells by doxorubicin-immunoliposomes directed by monoclonal antibodies specific to RON receptor tyrosine kinase.Self-Assembled Hydrogel Nanoparticles for Drug Delivery Applications.
P2860
Q27330365-08C47CF2-8020-4EF7-9370-535207A031DAQ28078448-E4986C29-B2A3-4298-B31E-DC73F7CDE9B0Q28480895-D9165010-2F7C-45AF-8987-C0460004CF3BQ28543911-D2115D75-7D84-4631-829B-5C987E7D58C7Q33605145-9906AA86-A834-4B19-B82E-93FD6FE500A6Q34340122-6F894DFB-FD05-4A73-BDF3-DEA5886287CAQ34565736-52225629-0BA2-4509-8E32-BA17A97CEC58Q35015474-BFA3A417-A877-4DCA-88BE-18BD0AA456B7Q36640650-FFDCE28E-E9C3-4C81-8640-1F7EC91BD96AQ37438909-ADCC348E-20B1-43EE-A045-27685AAF77D8Q37730085-CEE04EFC-AD8A-4470-BF35-CE5D554EDE7FQ38088348-1B6E9DE4-1B3A-4FFB-9360-76A176DBB4D4Q38132855-28655888-AE09-4A33-BDC8-94231223F3CFQ39084731-B8A9BC75-6911-46B1-95EF-DCCDE901F199Q39458547-6F490642-D815-4830-B42B-5BE123F46AAAQ39676024-1949B24B-C84A-4A79-81A4-F621FA0655D0Q47098115-7A296FF7-5AC9-419D-8A13-CE7999DC41C9
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 22 January 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Acute and chronic in vivo therapeutic resistance.
@en
Acute and chronic in vivo therapeutic resistance.
@nl
type
label
Acute and chronic in vivo therapeutic resistance.
@en
Acute and chronic in vivo therapeutic resistance.
@nl
prefLabel
Acute and chronic in vivo therapeutic resistance.
@en
Acute and chronic in vivo therapeutic resistance.
@nl
P1476
Acute and chronic in vivo therapeutic resistance.
@en
P2093
Beverly A Teicher
P304
P356
10.1016/J.BCP.2009.01.006
P407
P577
2009-01-22T00:00:00Z